<DOC>
	<DOCNO>NCT00573170</DOCNO>
	<brief_summary>Study TRX109011/TRX109013 , A Randomized , Double-blind , Double-dummy , Placebo-controlled , Crossover Study Evaluate Efficacy TREXIMET® ( Sumatriptan + Naproxen Sodium ) versus Butalbital-containing Combination Medications ( BCM ) Acute Treatment Migraine administer Moderate-Severe Pain Phase Migraine ( Studies 1 2 2 )</brief_summary>
	<brief_title>TREXIMET® Versus Butalbital-containing Combination Medications Acute Treatment Migraine Adults</brief_title>
	<detailed_description>This study multicenter , randomize , double-blind , double-dummy , placebo-controlled , crossover , three-attack , outpatient study TREXIMET® compare butalbital-containing combination medication ( BCM ; acetaminophen 325mg , caffeine 40mg , butalbital 50mg [ Fioricet ] ) acute treatment migraine headache . Subjects randomize one 6 possible treatment sequence ( TPB , TBP , BTP , BPT , PTB , PBT T = TREXIMET® ; P = Placebo ; B = Butalbital-containing Combination Medication ) . Subjects treat 3 migraine attack pain moderate severe . The study include 4 visit : ( 1 ) Screening visit study entry , ( 2 ) Drug Screen visit , ( 3 ) Randomization visit , ( 4 ) Final visit . The Final visit occur either ( A ) upon withdrawal ( B ) treatment 3 migraine attack . The primary objective evaluate efficacy TREXIMET® versus BCM acute treatment moderate/severe migraine . These two replicate study amend ongoing allow report pool data .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Males female age 18 65 year . Female subject eligible participation either nonchildbearing potential ( capable become pregnant ) OR childbearing potential negative urine pregnancy test screening , use contraception sexually active . If use oral contraceptive , subject stable regimen oral contraceptive ( &gt; /= 2 month ) . Eligible subject must : migraine without aura ( 2004 ICHDII criterion ) must least 2 attack per month meeting criterion three month prior screen . document use Butalbitalcontaining Combination Medication ( MCM ) treat least one migraine . able understand complete cognitive assessment questionnaires programmed electronic diary . willing able provide write informed consent . A subject eligible : &gt; 8 migraine &gt; /= 15 headache day per month total , retinal , basilar , hemiplegic migraine , secondary headache . take &gt; 350mg/day butalbital and/or barbiturate equivalent dose basis , average , 30 day prior screen . likely unrecognized cardiovascular cerebrovascular disease ( base history risk factor ) . blood pressure &gt; /= 140/90mmHg 2 3 BP measurement take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker . history congenital heart disease , cardiac arrhythmia require medication , clinical significant electrocardiogram abnormality . evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , signs/symptoms consistent . evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold ; treat antiepileptic drug seizure control within 5 year prior screen . history impaired hepatic renal function contraindicates participation study . hypersensitivity , allergy , intolerance , contraindication use triptan , NSAID , aspirin , barbiturate , acetaminophen ( include sumatriptan naproxen preparation ) , porphyria nasal polyp asthma . currently take , take previous three month , ergot preparation migraine prophylaxis ; take migraine prophylactic medication stabilize ( i.e . change dose within last 2 month ) either chronic intermittent migraine prophylaxis comorbid condition stabilize . recent history regular use opioids ( include opioids combination butalbital , e.g . Fioricet codeine ) barbiturates butalbital . Regular use define average 4 day per month last 6 month . take , plan take , monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) , anytime within 2 week prior screen 2 week post final study treatment . history bleed disorder currently take anticoagulant antiplatelet agent ( except lowdose aspirin &lt; /= 325mg/day cardioprotective reason ) . evidence history gastrointestinal surgery GI ulceration perforation past six month , gastrointestinal bleeding past year ; evidence history inflammatory bowel disease . pregnant , actively try become pregnant , breast feeding , willing pregnancy test perform . evidence alcohol substance abuse within last year concurrent medical psychiatric condition , investigator 's judgement , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical study . participate investigational drug trial within previous four week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Migraine , acute</keyword>
	<keyword>Migraine</keyword>
	<keyword>Butalbital-containing Combination Medication ( BCM )</keyword>
	<keyword>Naproxen sodium</keyword>
	<keyword>Sumatriptan succinate</keyword>
	<keyword>TREXIMET®</keyword>
</DOC>